KRB-456 binds with high affinity to KRAS G12D and KRAS G12V, decreases the cellular levels of GTP-bound KRAS, inhibits the binding of KRAS to RAF1 in pancreatic cancer cells, and inhibits in vivo tumor growth of subcutaneous and orthotopic xenografts from patients with pancreatic cancer. This evidence concerns the gene RAF1 and pancreatic neoplasm.